MedDataX Logo

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

NCT ID: NCT00034983

Last Updated: 2017-04-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-10-29

Study Completion Date

2003-12-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

NCT00035009

Major Depressive Disorder
COMPLETED PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

NCT00034944

Major Depressive Disorder
COMPLETED PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

NCT00048607

Major Depressive Disorder
COMPLETED PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

NCT00035295

Major Depressive Disorder
COMPLETED PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)

NCT00035282

Major Depressive Disorder
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The duration of treatment is 1 year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aprepitant

Intervention Type DRUG

Comparator: paroxetine HCL

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK0869

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Major Depressive Disorder
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

References

Explore related publications, articles, or registry entries linked to this study.

Snyder E, Cai B, DeMuro C, Morrison MF, Ball W. A New Single-Item Sleep Quality Scale: Results of Psychometric Evaluation in Patients With Chronic Primary Insomnia and Depression. J Clin Sleep Med. 2018 Nov 15;14(11):1849-1857. doi: 10.5664/jcsm.7478.

Reference Type DERIVED
PMID: 30373688 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Formally-497B

Identifier Type: -

Identifier Source: secondary_id

MK0869-066

Identifier Type: -

Identifier Source: secondary_id

2006_407

Identifier Type: -

Identifier Source: secondary_id

0869-066

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
NCT00035048 COMPLETED PHASE3
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
NCT00048594 COMPLETED PHASE3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
NCT00042029 COMPLETED PHASE3
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
NCT04937829 COMPLETED PHASE1
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
NCT00610649 COMPLETED PHASE2
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
NCT06785012 RECRUITING PHASE2
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
NCT00531622 COMPLETED PHASE3
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
NCT00733980 COMPLETED PHASE2
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
NCT01098240 TERMINATED PHASE2
This is a Study to Determine the Antidepressant Effects of AZD6765
NCT00986479 COMPLETED PHASE2
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111539 TERMINATED PHASE3
Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
NCT01380704 COMPLETED PHASE1
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
NCT02749721 COMPLETED PHASE4
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01123707 TERMINATED PHASE3
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
NCT00358631 COMPLETED PHASE2
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401 RECRUITING PHASE3
AZD6765 for Treatment Resistant Depression
NCT00491686 COMPLETED PHASE2
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111552 TERMINATED PHASE3
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
NCT01741142 TERMINATED PHASE2
Clinical Study to Test a New Drug to Treat Major Depression
NCT00976560 COMPLETED PHASE2
A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder
NCT01034995 COMPLETED PHASE2
Treatment of Depression in Adults
NCT00073697 COMPLETED PHASE4
Study to Treat Major Depressive Disorder (MDD) With a New Medication
NCT02149836 COMPLETED PHASE2
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
NCT00759395 COMPLETED PHASE2
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
NCT00566202 COMPLETED PHASE2